Breakout Session 1 Genomics And Pharmacogenomics Issues

Genomics and Pharmacogenomics

• Lack of evidence for many outcomes.
• Herceptin and gleevec examples
• Need to include pats. clinical information
• CPOE used to suggest tests that are needed before certain drugs can by ordered.
• Use case for data stored in the EDW.
• Lack of actually understanding outcomes

Genomics and Pharmacogenomics

• Need standards for patient data representation.
• Outcomes vs Observations?
• Future of gene therapy….different topic and hard to do
• Pharma interest in showing pat. X would benefit from expensive new drug
• Big benefit…viox, who can take drug.

Genomics and Pharmacogenomics

• Comparative effectiveness questions? Who responds to what therapy?
• Genetic data only suggests that drug X may be more effective.
• Dosing usually based on population data.
• Wafarin case for intelligent dosing.

Genomics and Pharmacogenomics Action Items

• Work bench, collaborative space or federated data structure, based on standards and motivated by need to prove better outcomes and provide decent observations (what the data are?).
• Creation of infrastructure to define of principles or policy for ethical and legal issues.
• Creation of resources to define the barriers for clinical research infrastructure.
• Need for AMIA/ACMI education in pharmacogenomics (meetings and publications)
• Need to be clear what actions we are trying to deal with.
• Need to determine who the stakeholders are.

Unless otherwise stated, the content of this page is licensed under Creative Commons Attribution-ShareAlike 3.0 License